PIMR, a novel Kunitz-type protease inhibitor from the Macrovipera razii, with dual anticoagulant and anticancer activities
Biochimie · 2026
DOI: 10.1016/j.biochi.2025.11.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochimie, 2026. Verfasst von Pegah Moshtaghian und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics, Faculty of Science, Shahrekord University, Shahrekord, Iran. Hauptthemen laut MEDLINE: Antineoplastic Agents, Anticoagulants, Viperidae, Viper Venoms. Die Arbeit nennt 47 Literaturangaben. Gefördert von: Shahrekord University.
Abstract (Originalsprache)
Snake venom is a rich source of bioactive peptides with diverse pharmacological effects. Kunitz-type protease inhibitors are one of the multifunctional peptides isolated from the snake venom. The Razi's viper, Macrovipera razii, is a species endemic to Iran whose venom components are still largely unexplored. In this study, we report the isolation, cloning, and functional characterization of PIMR, a novel Kunitz-type protease inhibitor derived from M. razii venom. The gene encoding PIMR was amplified from venom gland cDNA and then cloned into a prokaryotic expression vector. The PIMR protein consists of 71 residues stabilized by three disulfide bonds, characteristic of the folded Kunitz domain. Recombinant PIMR was expressed in Escherichia coli and purified by affinity chromatography. The anticoagulant activity of PIMR was assessed by clotting time, prothrombin time, and activated partial thromboplastin time assays. The results indicated a dose-dependent anticoagulant activity of the peptide. The PIMR also exhibited anticancer effects against the highly invasive breast cancer cell line, MDA-MB-231, with an IC50 of 33 μg/μl. Docking studies indicated that the RGN motif of PIMR interacts with integrins, suggesting a potential mechanism for inhibiting cancer cell proliferation. Additionally, molecular docking confirmed binding of PIMR to trypsin, supporting its role as a serine protease inhibitor. Our findings establish PIMR as a novel serine protease inhibitor with promising anti-coagulant and anti-cancer properties. PIMR, with its diverse biological functions, represents a potential candidate for drug development and further molecular investigations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Genetics, Faculty of Science, Shahrekord University, Shahrekord, Iran.
- Department of Genetics, Faculty of Science, Shahrekord University, Shahrekord, Iran. Electronic address: ayat-h@sku.ac.ir.
- Department of Zoology, Faculty of Science, Shahrekord University, Shahrekord, Iran.
Förderung
- Shahrekord University
Zitieren
APA
Moshtaghian, P., Ayat, H., Ahadi, A. M., & Oraie, H. (2026). PIMR, a novel Kunitz-type protease inhibitor from the Macrovipera razii, with dual anticoagulant and anticancer activities. Biochimie. https://doi.org/10.1016/j.biochi.2025.11.005
Vancouver
Moshtaghian P, Ayat H, Ahadi AM, Oraie H. PIMR, a novel Kunitz-type protease inhibitor from the Macrovipera razii, with dual anticoagulant and anticancer activities. Biochimie. 2026. doi:10.1016/j.biochi.2025.11.005
BibTeX
@article{Moshtaghian2026,
author = {Moshtaghian, Pegah and Ayat, Hoda and Ahadi, Ali Mohammad and Oraie, Hamzeh},
title = {PIMR, a novel Kunitz-type protease inhibitor from the Macrovipera razii, with dual anticoagulant and anticancer activities},
journal = {Biochimie},
year = {2026},
doi = {10.1016/j.biochi.2025.11.005}
}
EUVIMED